Tag: bioinformatics in in-vitro diagnostics testing market insights

Uncover key drivers, emerging technologies, and competitive movements shaping the bioinformatics in in-vitro diagnostics (ivd) testing market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market from 2026 to 2030?

The bioinformatics in in-vitro diagnostics (ivd) testing market size has experienced strong growth in recent years. It is anticipated to expand from $98.89 billion in 2025 to $105.59 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.8%. The market’s historical growth can be attributed to the increasing volumes of molecular diagnostic testing, the rising adoption of next-generation sequencing in diagnostics, the proliferation of centralized diagnostic laboratories, the availability of advanced diagnostic hardware, and the greater use of data-driven clinical decision support.

The bioinformatics in in-vitro diagnostics (ivd) testing market is projected for substantial expansion in the coming years. This market is anticipated to reach $133.49 billion by 2030, showing a compound annual growth rate (CAGR) of 6.0%. This anticipated growth over the forecast period stems from several factors, including the surging need for precision diagnostics, the broadening scope of personalized medicine diagnostics, heightened investments in AI-powered diagnostic platforms, the expanding application of cloud-based diagnostic analytics, and greater regulatory endorsement of digital diagnostics. Key trends during this period encompass the increasing deployment of AI-driven diagnostic interpretation software, the heightened embrace of cloud-enabled IVD bioinformatics platforms, the growing consolidation of molecular and clinical data, the broadening of companion diagnostics analytics, and a stronger emphasis on processing diagnostic data in real-time.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16629&type=smp

What Drivers Are Affecting Demand In The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market?

The rising incidence of cancer is anticipated to fuel the expansion of bioinformatics within the IVD testing market in the future. Cancer itself is a collective term for conditions marked by uncontrolled cell proliferation, capable of invading and metastasizing throughout the body. This growing prevalence of cancer stems from diverse factors including environmental exposures, lifestyle choices, and other external influences. In the realm of IVD testing, bioinformatics revolutionizes cancer diagnostics by delivering accurate, tailored, and exhaustive genetic data, thereby improving early diagnosis, guiding therapeutic choices, and ultimately bettering patient prognoses. As an illustration, the World Health Organization, a specialized agency of the United Nations based in Switzerland, reported in February 2024 that over 35 million new cancer cases are predicted in 2050. Consequently, the escalating occurrence of cancer acts as a primary catalyst for the bioinformatics sector within the IVD testing market.

Which Segment Groups Are Influencing The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market?

The bioinformatics in in-vitro diagnostics (ivd) testing market covered in this report is segmented –

1) By Component: Hardware, Software

2) By Type Of Test: Blood Based Tests, Tissue Based Tests

3) By Application: Cardiovascular Diseases, Chronic Diseases, Diabetes, Cancer, Other Applications

Subsegments:

1) By Hardware: Analyzers, Laboratory Equipment, Data Storage Devices, Sensors And Detectors, Workstations And Data Processing Hardware

2) By Software: Bioinformatics Platforms, Data Management and Integration Software, Analytics And Interpretation Software, Cloud-Based Software Solutions, AI-Based Software For Diagnostics

What Trends Are Projected To Support The Growth Of The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market?

Companies operating within the bioinformatics in the IVD testing market are concentrating on developing innovative solutions, such as next-generation sequencing (NGS) technology. These advancements aim to enhance the detection and analysis of genetic mutations, improve diagnostic accuracy, and facilitate personalized medicine approaches. Next-generation sequencing (NGS) itself is a high-throughput technology that enables the rapid sequencing of entire genomes or specific DNA and RNA regions, allowing for comprehensive genetic analysis. For example, in January 2024, QIAGEN Digital Insights, the bioinformatics division of the Netherlands-based molecular diagnostics company QIAGEN, introduced LightSpeed. This ultra-fast NGS (next-generation sequencing) secondary-analysis software accelerator is integrated into its CLC Genomics Workbench Premium platform. The LightSpeed module allows laboratories to process somatic cancer NGS data with unprecedented speed, converting raw sequencing files (FASTQ) into variant calls (VCF) in just minutes, while simultaneously reducing the cost per sample. LightSpeed supports high-throughput cancer panels and is compatible with both cloud-based and on-premises workflows, empowering bioinformatics teams to quickly analyze multiple tumor genes and biomarkers from a single sample to guide precision oncology decision-making.

Who Are The Major Companies Operating In The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market?

Major companies operating in the bioinformatics in in-vitro diagnostics (ivd) testing market are Illumina Inc, Thermo Fisher Scientific Inc, QIAGEN N.V, Agilent Technologies Inc, PerkinElmer Inc, Roche Holding AG, BGI Genomics Co Ltd, DNAnexus Inc, Seven Bridges Genomics Inc, Dassault Systèmes SE (BIOVIA), Genedata AG, Partek Inc, Data4Cure Inc, Ontoforce NV, Geneious (Biomatters), SoftGenetics LLC, Eagle Genomics Ltd, Wuxi NextCODE Genomics, Bio‑Rad Laboratories Inc, Eurofins Scientific SE

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/bioinformatics-in-in-vitro-diagnostics-ivd-testing-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market?

North America was the largest region in the bioinformatics in in-vitro diagnostics (IVD) testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioinformatics in in-vitro diagnostics (ivd) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16629&type=smp

Browse Through More Reports Similar to the Global Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market 2026, By The Business Research Company

Biologics Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

In Vitro Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-global-market-report

In Vitro Diagnostics Ivd Quality Control Market Report 2026

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-ivd-quality-control-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Projected Valuation Of The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market In The Coming Years?

The market size of bioinformatics in in-vitro diagnostics (ivd) testing has seen a significant increase in the past years. The projection is that it will escalate from $93.02 billion in 2024 to $98.89 billion in 2025, with a compound annual growth rate (CAGR) of 6.3%. The growth experienced in the historical period is credited to factors such as the enhancement of healthcare infrastructure, expansion of biobanks, a surge in the elderly population, governmental initiatives and funding, along with the growth in personalized medicine.

The market size of bioinformatics in in-vitro diagnostics (ivd) testing is set to witness robust growth in the upcoming years, with predictions suggesting it will ascend to $126.76 billion by 2029 with a compound annual growth rate (CAGR) of 6.4%. This escalating growth over the forecast period is attributed to various factors including the increasing incidence of diseases, incorporation of IT in the healthcare sector, governmental support, a shift towards precision medicine, increasing consciousness about bioinformatics’ advantages in diagnostics amongst healthcare professionals, and a reduction in the cost of genomic sequencing. The forecast period is expected to see major trends such as artificial intelligence (AI) and machine learning, next-generation sequencing, point-of-care (POC) testing, cloud computing coupled with big data, and developments in immunochemical techniques.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16629&type=smp

What Drivers Are Accelerating Expansion Of The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market?

The growth of the bioinformatics in IVD testing market is anticipated to surge owing to the rising prevalence of cancer. Cancer is a generic term encompassing a myriad of diseases marked by unusual cell growth capable of invading and diffusing to various other body components. Factors such as exposure, lifestyle choices, and environmental factors primarily contribute to the escalating instances of Cancer. The advent of bioinformatics in IVD testing revolutionizes cancer diagnosis by delivering precise, individualized, and broad genetic revelations, thereby promoting early detection, informed treatment selection, and improved patient prognoses. For example, the National Association of Chronic Disease Directors (NACDD), a US government agency, reported in 2022 that approximately 40% of American adults contend with multiple chronic conditions (MCC). There’s a mounting body of evidence suggesting that the presence of one chronic ailment elevates the chances of contracting more, particularly with advancing age. These rising instances of Cancer hence catalyze the bioinformatics in the IVD testing market.

How Is The Global Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Broken Down By Segment?

The bioinformatics in in-vitro diagnostics (ivd) testingmarket covered in this report is segmented –

1) By Type: Hardware; Software

2) By Type Of Test: Blood Based Tests; Tissue Based Tests

3) By Application: Cardiovascular Diseases; Chronic Diseases; Diabetes; Cancer; Other Applications

Subsegments:

1) By Hardware: Analyzers; Laboratory Equipment; Data Storage Devices; Sensors And Detectors; Workstations And Data Processing Hardware

2) By Software: Bioinformatics Platforms; Data Management and Integration Software; Analytics And Interpretation Software; Cloud-Based Software Solutions; AI-Based Software For Diagnostics

Which Market Trends Are Expected To Define The Future Of The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market?

Major firms in the bioinformatics space of the IVD testing market are shifting their focus towards the creation of innovative solutions like next-generation sequencing (NGS) technology. This technology has the potential to enhance the ability to detect and analyse genetic mutations, increase the precision of diagnostics, and aid in the implementation of personalized medicine. Next-generation sequencing is a highly efficient technology that enables the quick sequencing of complete genomes or specified DNA and RNA regions, paving the way for extensive genetic investigations. For instance, Illumina Inc., a major player in the biotechnological space based in the US, unveiled a new pan-cancer companion diagnostic indication for its CE-marked TruSight Oncology Comprehensive (EU) test, in May 2022. This advanced test can identify cancer sufferers with solid tumors exhibiting NTRK gene fusions, primarily NTRK1, NTRK2, or NTRK3, who may potentially benefit from the use of targeted therapy with Bayer’s drug Vitrakvi. The TruSight Oncology Comprehensive (EU) test is a comprehensive genomic profiling assay that employs next-generation sequencing to analyze numerous tumor genes and biomarkers from a single biopsy sample to ascertain a patient’s unique cancer genomic makeup.

Which Firms Are Making The Biggest Impact In The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market?

Major companies operating in the bioinformatics in in-vitro diagnostics (IVD) testing market are Siemens Healthineers, International Business Machines Corporation, Medtronic Inc., Parker Hannifin Corp., Illumina Inc, PerkinElmer Inc., QIAGEN N.V., Kollmorgen Corp, Bioreference Laboratories Inc., AssureRx Health Inc., Biodesix Inc., Crescendo Bioscience Inc., Affymetrix, Complete Genomics Inc., Aperico Technologies Inc., One Lambda Inc., Datech Oncology, Life Technologies, Signal genetics, CardioDx Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/bioinformatics-in-in-vitro-diagnostics-ivd-testing-global-market-report

Which Geographic Regions Are Creating Strong Demand In The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market?

North America was the largest region in the bioinformatics in in-vitro diagnostics (IVD) testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioinformatics in in-vitro diagnostics (IVD) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=16629&type=smp

Browse Through More Reports Similar to the Global Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market 2025, By The Business Research Company

In Vitro Diagnostics Ivd Quality Control Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-ivd-quality-control-global-market-report

In Vitro Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-global-market-report

Bioinformatics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bioinformatics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Size During 2025–2029?

The bioinformatics in in-vitro diagnostics (ivd) testing market has demonstrated robust expansion over recent years. Its valuation is expected to ascend from $93.02 billion in 2024 to $98.89 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.3%. This historical growth can be ascribed to factors such as better healthcare infrastructure, the proliferation of biobanks, an increasing elderly demographic, various government initiatives and funding mechanisms, and the advancement of personalized medicine.

The market for bioinformatics in in-vitro diagnostics (IVD) testing is projected to experience robust expansion over the coming years. This market is forecast to reach $126.76 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.4%. Several factors contribute to this projected increase, including an escalating incidence of diseases, the incorporation of IT within healthcare, governmental support and investment, a move towards tailored medical approaches, greater understanding of bioinformatics advantages in diagnostics among medical professionals, and a reduction in genomic sequencing expenses. Key developments anticipated during this timeframe encompass artificial intelligence (AI) and machine learning, next-generation sequencing, point-of-care (POC) testing, cloud computing and big data, alongside advancements in immunochemical methodologies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16629&type=smp

What Are The Drivers Pushing New Developments In The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market?

The escalating incidence of cancer is anticipated to drive the expansion of the bioinformatics in IVD testing market in the future. Cancer is a broad categorization for diseases characterized by uncontrolled cell growth, which can invade and spread to other parts of the body. The increasing frequency of cancer can be attributed to various factors such as exposure, lifestyle, and environmental influences. Bioinformatics in IVD testing revolutionizes cancer diagnostics by delivering precise, personalized, and comprehensive genetic data, thereby enhancing early detection, informing treatment decisions, and improving patient outcomes. For instance, in 2022, the National Association of Chronic Disease Directors (NACDD), a U.S.-based government agency, reported that approximately 40% of American adults live with multiple chronic conditions (MCC), and there is increasing evidence that possessing one chronic illness raises the risk of acquiring additional ones, especially with advancing age. Therefore, the rising prevalence of cancer fuels the bioinformatics in the IVD testing market.

What Are The Emerging Segments Gaining Attention In The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market?

The bioinformatics in in-vitro diagnostics (ivd) testingmarket covered in this report is segmented –

1) By Type: Hardware; Software

2) By Type Of Test: Blood Based Tests; Tissue Based Tests

3) By Application: Cardiovascular Diseases; Chronic Diseases; Diabetes; Cancer; Other Applications

Subsegments:

1) By Hardware: Analyzers; Laboratory Equipment; Data Storage Devices; Sensors And Detectors; Workstations And Data Processing Hardware

2) By Software: Bioinformatics Platforms; Data Management and Integration Software; Analytics And Interpretation Software; Cloud-Based Software Solutions; AI-Based Software For Diagnostics

What Trends Are Expected To Drive The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market?

Leading companies active in the bioinformatics in the IVD testing market are focusing on creating advanced solutions, such as next-generation sequencing (NGS) technology, to boost the detection and analysis of genetic mutations, refine diagnostic accuracy, and support personalized medicine strategies. Next-generation sequencing (NGS) represents a high-throughput method facilitating the rapid sequencing of entire genomes or specific DNA and RNA regions, thereby enabling comprehensive genetic analysis. For instance, in May 2022, Illumina Inc., a US-based biotechnology company, unveiled a new pan-cancer companion diagnostic (CDx) indication for its CE-marked TruSight Oncology Comprehensive (EU) test. This advancement enables the test to identify cancer patients with solid tumors who possess neurotrophic tyrosine receptor kinase (NTRK) gene fusions, specifically NTRK1, NTRK2, or NTRK3, and who might benefit from targeted therapy with Bayer’s drug Vitrakvi (larotrectinib). The TSO Comprehensive (EU) test functions as a comprehensive genomic profiling (CGP) assay, incorporating next-generation sequencing to analyze numerous tumor genes and biomarkers from a single biopsy specimen to ascertain a patient’s distinct cancer molecular profile.

Who Are The Prominent Global Companies Shaping The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market?

Major companies operating in the bioinformatics in in-vitro diagnostics (IVD) testing market are Siemens Healthineers, International Business Machines Corporation, Medtronic Inc., Parker Hannifin Corp., Illumina Inc, PerkinElmer Inc., QIAGEN N.V., Kollmorgen Corp, Bioreference Laboratories Inc., AssureRx Health Inc., Biodesix Inc., Crescendo Bioscience Inc., Affymetrix, Complete Genomics Inc., Aperico Technologies Inc., One Lambda Inc., Datech Oncology, Life Technologies, Signal genetics, CardioDx Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/bioinformatics-in-in-vitro-diagnostics-ivd-testing-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market?

North America was the largest region in the bioinformatics in in-vitro diagnostics (IVD) testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioinformatics in in-vitro diagnostics (IVD) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Report:

https://www.thebusinessresearchcompany.com/customise?id=16629&type=smp

Browse Through More Reports Similar to the Global Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market 2025, By The Business Research Company

In Vitro Diagnostics Ivd Quality Control Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-ivd-quality-control-global-market-report

In Vitro Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-global-market-report

Bioinformatics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bioinformatics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What is the Anticipated CAGR of the Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market, and What Factors Will Drive It?

The bioinformatics in in-vitro diagnostics (ivd) testing market has seen a robust expansion in recent years. Projected growth will see it rise from $93.02 billion in 2024 to $98.89 billion in 2025, with a compound annual growth rate (CAGR) of 6.3%. Factors contributing to growth during the historic period include enhanced healthcare infrastructure, enlargement of biobanks, an increase in the elderly population, government funding and initiatives, and the development of personalized medicine.

Expectations are high for the bioinformatics in in-vitro diagnostics (ivd) testing market as it is predicted to witness robust growth in the coming years, scaling up to an impressive$126.76 billion by 2029 at a compound annual growth rate (CAGR) of 6.4%. The anticipated growth during the forecast period could be due to an increase in disease incidence rates, the integration of technology in healthcare, robust government initiatives and financial aid, a shift towards personalized medicine, improved understanding of the advantages of bioinformatics in diagnostics amongst healthcare professionals, and the reduction in the cost of genomic sequencing. The projection period is poised to see major advancements such as artificial intelligence (AI) and machine learning, next-generation sequencing, point-of-care (POC) testing, cloud computing and big data, along with breakthroughs in immunochemical techniques.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16629&type=smp

Which Primay Drivers Are Accelerating Growth in the Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market?

The continual rise in cancer occurrences is predicted to fuel the expansion of the bioinformatics in IVD testing market. Cancer broadly refers to a multitude of diseases marked by abnormal cell growth, capable of invading and spreading throughout the body. The surge in cancer occurrences is attributable to an array of factors that include exposure, lifestyle, and environmental causes. The application of bioinformatics in IVD testing revolutionizes cancer diagnosis by offering accurate, individualized, and thorough genetic insights that improve early detection, the processes of choosing treatments, and patient results. For instance, in 2022, as per the National Association of Chronic Disease Directors (NACDD), a government agency based in the US, it had been found that around 40% of American adults live with multiple chronic conditions (MCC). There is a mounting evidence suggesting that having one chronic illness amplifies the risk of developing more, particularly with advancing age. Hence, the constant rise in cancer occurrences propels the growth of the bioinformatics in the IVD testing market.

Which Primary Segments of the Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Are Driving Growth and Industry Transformations?

The bioinformatics in in-vitro diagnostics (ivd) testingmarket covered in this report is segmented –

1) By Type: Hardware; Software

2) By Type Of Test: Blood Based Tests; Tissue Based Tests

3) By Application: Cardiovascular Diseases; Chronic Diseases; Diabetes; Cancer; Other Applications

Subsegments:

1) By Hardware: Analyzers; Laboratory Equipment; Data Storage Devices; Sensors And Detectors; Workstations And Data Processing Hardware

2) By Software: Bioinformatics Platforms; Data Management and Integration Software; Analytics And Interpretation Software; Cloud-Based Software Solutions; AI-Based Software For Diagnostics

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=16629&type=smp

Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market?# Market?

North America was the largest region in the bioinformatics in in-vitro diagnostics (IVD) testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioinformatics in in-vitro diagnostics (IVD) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Technological Trends Are Reshaping the Bioinformatics In In-Vitro Diagnostics (IVD) Testing Industry Dynamics?

Leading firms in the bioinformatics in the IVD testing market are increasingly focusing on the creation of innovative solutions such as next-generation sequencing (NGS) to augment detection and analysis of genetic abnormalities, refine diagnostic precision, and foster approaches in personalized medicine. NGS is a technology with a high-throughput, which facilitates instantaneous sequencing of entire genomes or targeted DNA and RNA regions, allowing for an exhaustive genetic inspection. For example, in May 2022, Illumina Inc., a biotech firm based in the US, presented a new pan-cancer companion diagnostic (CDx) indication for its TruSight Oncology Comprehensive (EU) test carrying the CE mark. This enables the test to identify cancer patients carrying solid tumors exhibiting neurotrophic tyrosine receptor kinase (NTRK) gene fusions such as NTRK1, NTRK2, or NTRK3, who might find targeted therapy with Bayer’s Vitrakvi (larotrectinib) beneficial. The TSO Comprehensive (EU) test is a comprehensive genomic profiling (CGP) assay that comprises next-generation sequencing which evaluates multiple tumor genes and biomarkers from a singular biopsy specimen, helpful in discerning a patient’s individual cancer molecular profile.

View the full report here:

https://www.thebusinessresearchcompany.com/report/bioinformatics-in-in-vitro-diagnostics-ivd-testing-global-market-report

What Parameters Are Used to Define the Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market?

Bioinformatics in in vitro diagnostics (IVD) refers to the application of computational methods, data analysis, and software tools to interpret and analyze biological data generated from in vitro diagnostic tests. It involves using algorithms and statistical models to process large volumes of molecular and clinical data from diagnostic tests conducted outside the living organism (in vitro).

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16629

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theBioinformatics In In-Vitro Diagnostics (IVD) Testing Market?

The continuous rise in cancer cases is anticipated to drive the expansion of the bioinformatics in IVD testing market. Cancer represents a collection of diseases marked by uncontrolled cell growth that can proliferate and migrate to various parts of the body. The hike in cancer cases attributes to multiple factors, those include exposure, lifestyle, and environmental aspects. The incorporation of bioinformatics into IVD testing revolutionizes cancer diagnosis by offering accurate, individualized, and thorough genetic insights that improve early detection, treatment options, and patient results. As per the 2022 data from the National Association of Chronic Disease Directors (NACDD), a government agency based in the US, roughly 40% of American adult population endure multiple chronic conditions (MCC), and emerging evidence indicates that a single chronic illness increases the likelihood of developing more, particularly in older age. Thus, the rising prevalence of cancer furthers the growth of the bioinformatics in the IVD testing market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16629&type=smp

What is the Predicted Annual Growth Rate of theBioinformatics In In-Vitro Diagnostics (IVD) Testing Market Impact Industry Trends by 2034?

The market size for bioinformatics in in-vitro diagnostics (IVD) testing has witnessed significant growth in recent years. The market is projected to expand from $93.02 billion in 2024 to $99.69 billion in 2025, with a compound annual growth rate (CAGR) of 7.2%. The historical growth trend can be ascribed to factors such as enhancement in healthcare infrastructure, expansion of biobanks, a growing elderly population, supportive government schemes and funding, as well as the evolution of personalized medicine.

Predictions indicate robust growth for the bioinformatics in in-vitro diagnostics (IVD) testing market in the coming years. The market is anticipated to expand to $129.89 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 6.8%. This expected growth in the forecast period can be attributed to various factors like increasing disease prevalence, integration of IT into healthcare, government funding and initiatives, the transition towards personalized medicine, heightened awareness about the benefits of bioinformatics in diagnostics among healthcare providers, and a reduction in the cost of genomic sequencing. The forecast period is also expected to witness major trends such as artificial intelligence (AI) and machine learning, next-generation sequencing, point-of-care (POC) testing, cloud computing and big data, and advancements in immunochemical techniques.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16629

What Are the Current Market Growth and Trends in theBioinformatics In In-Vitro Diagnostics (IVD) Testing Market That Industry Players Should Watch?

Key players in the IVD bioinformatics market are concentrating on the evolution of novel solutions including next-generation sequencing (NGS) methods. The aim is to advance the pinpointing and examination of genetic aberrations, boost diagnostic precision, and advance personalized treatment strategies. NGS is a potent technology that facilitates swift sequencing of whole genomes or selective DNA and RNA regions, thereby enabling extensive genetic scrutiny. One such case involves Illumina Inc., an American biotech firm, which in May 2022 rolled out a novel pan-cancer companion diagnostic (CDx) indication for their CE-marked TruSight Oncology Comprehensive (EU) test. This makes possible the recognition of cancer patients suffering from solid tumors who have neurotrophic tyrosine receptor kinase (NTRK) gene fusions, such as NTRK1, NTRK2, or NTRK3, and who may derive benefits from Bayer’s Vitrakvi (larotrectinib) targeted therapy. The TSO Comprehensive (EU) test is a complete genomic profiling (CGP) assay that incorporates next-generation sequencing to analyze numerous tumor genes and markers from a single biopsy, in order to ascertain a patient’s unique cancer molecular profile.

What Are the Major Market Players Making an Impact on theBioinformatics In In-Vitro Diagnostics (IVD) Testing Market Growth?

Major companies operating in the bioinformatics in in-vitro diagnostics (IVD) testing market are Siemens Healthineers, International Business Machines Corporation, Medtronic Inc., Parker Hannifin Corp., Illumina Inc, PerkinElmer Inc., QIAGEN N.V., Kollmorgen Corp, Bioreference Laboratories Inc., AssureRx Health Inc., Biodesix Inc., Crescendo Bioscience Inc., Affymetrix, Complete Genomics Inc., Aperico Technologies Inc., One Lambda Inc., Datech Oncology, Life Technologies, Signal genetics, CardioDx Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/bioinformatics-in-in-vitro-diagnostics-ivd-testing-global-market-report

How Are the Key Segments of the Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Driving Opportunities and Innovations?

The bioinformatics in in-vitro diagnostics (IVD) testing market covered in this report is segmented –

1) By Type: Hardware, Software

2) By Type Of Test: Blood Based Tests, Tissue Based Tests

3) By Application: Cardiovascular Diseases, Chronic Diseases, Diabetes, Cancer, Other Applications

Subsegments:

1) By Hardware: Analyzers, Laboratory Equipment, Data Storage Devices, Sensors And Detectors, Workstations And Data Processing Hardware

2) By Software: Bioinformatics Platforms, Data Management and Integration Software, Analytics And Interpretation Software, Cloud-Based Software Solutions, AI-Based Software For Diagnostics

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=16629&type=smp

What Regions Are At the Forefront of #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theBioinformatics In In-Vitro Diagnostics (IVD) Testing Market?# Market Expansion?

North America was the largest region in the bioinformatics in in-vitro diagnostics (IVD) testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioinformatics in in-vitro diagnostics (IVD) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market 2025, By The Business Research Company:

In Vitro Diagnostics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-global-market-report

Hospital Acquired Infections Testing Kits Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/hospital-acquired-infections-testing-kits-global-market-report

AI In Bioinformatics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/ai-in-bioinformatics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: